ReNeuron licenses rights to its CTX and hRPC cell therapy programmes to Fosun Pharma for Chinese market

ReNeuron to receive upfront, near term and estimated success-based milestone payments of £80.0 million (US$104.8 million) and double-digit royalties on sales

09 April 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has signed an exclusive licence agreement (“the Agreement”) with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”), for the development, manufacture and commercialisation of ReNeuron’s CTX and hRPC cell therapy programmes in the People’s Republic of China (“China”).

Read more…

Back